U.S. President Trump has announced his intention to impose a 100% tariff on imported generic drugs beginning in 2028, aiming to encourage the establishment of domestic production facilities within the United States [1]. Trump stated that this strong countermeasure against inexpensive overseas generic drugs is designed to protect the American pharmaceutical industry [1].
Market participants have expressed concerns that the introduction of a 100% tariff would inevitably lead to higher prices for generic drugs, potentially increasing the burden on both the healthcare insurance system and patients [1]. There is also speculation that this policy could impact the stock prices of pharmaceutical manufacturers and the distribution industry, with close attention being paid to future developments [1].
Industry groups and consumer organizations have voiced opposition to the policy, and there is significant interest in the ongoing discussions and details of the proposed measures [1].
CONCLUSION
President Trump's plan to impose a 100% tariff on imported generic drugs from 2028 is expected to have significant repercussions for drug prices, the healthcare system, and related industries. The announcement has sparked opposition from industry and consumer groups, and market participants are closely monitoring the situation for further developments.